Cover Image

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison

Philip Hampton,1 Emma Borg,2 Jes Birger Hansen,2 Matthias Augustin3 1Department of Dermatology, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK; 2LEO Pharma A/S, Ballerup, Denmark; 3Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Cen...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hampton P (Author), Borg E (Author), Hansen JB (Author), Augustin M (Author)
Format:	Book
Published:	Dove Medical Press, 2021-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
by: Kristian Reich, et al.
Published: (2024)

Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline Psoriasis Area and Severity Index from week 4 to 40
by: Richard G. Langley, MD, et al.
Published: (2024)

Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab
by: Reem Kashlan, MPH, et al.
Published: (2021)

Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2024)

Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics
by: Alan Menter, et al.
Published: (2020)

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2023)

Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2023)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
by: Light JG, et al.
Published: (2021)

Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis
by: April W. Armstrong, et al.
Published: (2024)

Pityriasis Rubra Pilaris refractory to ustekinumab successfully treated with guselkumab
by: João Teixeira, et al.
Published: (2024)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
by: Cacciapuoti S, et al.
Published: (2023)

Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
by: Roman M, et al.
Published: (2017)

A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis-IL PSO (Italian Landscape Psoriasis)
by: Mario Valenti, et al.
Published: (2024)

Clinical observation of guselkumab in the treatment of 23 cases of moderate to severe plaque psoriasis
by: Liye XIA, et al.
Published: (2024)

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
by: Galluzzo M, et al.
Published: (2019)

The use of ustekinumab and guselkumab in a pediatric psoriasis patient with active hepatitis B infection
by: Eingun James Song, MD, FAAD, et al.
Published: (2021)

Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
by: Tiago Torres, et al.
Published: (2024)

Matching-Adjusted Indirect Comparisons in the assessment of hemato-oncological drugs
by: Francisco Javier Parrondo-García, et al.
Published: (2021)

Guselkumab in the treatment of patients with plaque psoriasis of moderate and severe severity: Efficacy and safety of interleukin-23 blockade
by: V. V. Chikin
Published: (2020)

Brodalumab
by: Murat Borlu
Published: (2022)

Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic
by: Spyridon Gkalpakiotis, et al.
Published: (2023)

Practical experience of ustekinumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to previous tumor necrosis factor blockers
by: Tzu-Chang Wang, et al.
Published: (2015)

Achievement and maintenance of therapeutic response to brodalumab in patients with moderate‐to‐severe plaque psoriasis: An Italian, observational, retrospective and prospective study (BRIGHT study)
by: Paolo Dapavo, et al.
Published: (2023)

Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Difamilast 1% and Delgocitinib 0.5% in Patients with Moderate-to-Severe Atopic Dermatitis
by: Takeshi Nakahara, et al.
Published: (2024)

Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review
by: Pinter A, et al.
Published: (2019)

Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
by: Kristian Reich, et al.
Published: (2022)

Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: a Narrative Review
by: Maria Vittoria Cannizzaro, et al.
Published: (2023)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
by: Jerry Bagel, et al.
Published: (2018)

Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice
by: Yi-Teng Hung, et al.
Published: (2021)

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
by: Kim Rand, et al.
Published: (2023)

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
by: Yang EJ, et al.
Published: (2019)

Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
by: Kim Rand, et al.
Published: (2024)

Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison
by: Ronan Mahon, et al.
Published: (2024)

Model-Informed Precision Dosing for Personalized Ustekinumab Treatment in Plaque Psoriasis
by: Karine Rodríguez-Fernández, et al.
Published: (2024)

Seven cancer patients receiving Guselkumab for treatment of moderate-to-severe psoriasis
by: Luca Mastorino, et al.
Published: (2022)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
by: Marloes E. van Muijen, et al.
Published: (2022)

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient: a case report
by: Nicoletta Bernardini, et al.
Published: (2022)

Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'
by: Mike Bastian, et al.
Published: (2024)

Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'"
by: Kim Rand, et al.
Published: (2024)

Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis
by: James Signorovitch, et al.
Published: (2023)